The pathogenesis of GvHD involves migration of donor T-cells into the secondary lymphoid organs in the recipient, which is steered by two homing molecules, CD62L and CCR7. Therefore, we investigated whether the migratory capacity of donor T-cells is associated with GvHD. This single center prospective study included 85 donor-recipient pairs. In vitro chemotaxis assays of the lymphocytes of the apheresis product were performed in parallel to the analysis of CD62L and CCR7 by flow cytometry. The migratory index to the CCR7 ligands, CCL19 and CCL21, was higher in T-cells from donors whose recipients will develop GvHD. Similarly, the acute GvHD (aGvHD) group received higher percentage of CD4+CCR7+ T-cells, whereas chronic GvHD (cGvHD) patients were transplanted with higher percentages of CD8+CCR7+ T-cells compared with the non-GvHD group. These results were confirmed when patients were subdivided according to degrees of severity. Further, multivariate analysis confirmed that the proportions of CCR7+ CD4+ and CCR7+ CD8+ T-cells are risk factors for the development and severity of aGvHD and cGvHD, respectively. Functional experiments demonstrated that CCR7+ T-cells exhibited higher potential for activation than CCR7-T-cells did. We therefore propose that the selective depletion of CCR7-expressing T-cells may be an effective preventive therapy for GvHD.
INTRODUCTION
GvHD remains a serious and common complication of allogeneic hematopoietic stem cell transplantation (HSCT) associated with significant morbidity and mortality. 1 GvHD is classically divided into acute and chronic forms. 2, 3 The reported incidence of acute GvHD (aGvHD) ranges between 9 and 50%, 4 whereas chronic GvHD (cGvHD) occurs in 30-70% of patients. 5 aGvHD can have devastating consequences on the skin, gut and liver, 6 whereas cGvHD is a syndrome of variable clinical features resembling autoimmune and other immunologic disorders. 7 The pathogenesis of aGvHD follows an accepted pathophysiological model that begins with a conditioning phase of the host which promotes a proinflammatory environment. 8 Once the graft is infused, the donor naïve T-cells migrate through the high endothelial venules to the secondary lymphoid organs (SLO) in a CCR7 and CD62L-dependent manner. 9 CD62L is an adhesion molecule involved in the early phases of lymphocyte rolling in the extravasation process. 10 CCR7 is a chemokine receptor that binds to CCL19 or CCL21 which in turn activate lymphocyte integrins, triggering firm arrest on the high endothelial venules surface. In addition, CCR7 directs T-cells to appropriate T-cell rich zones within the lymph node paracortex. 11 Once in the SLO, the lymphocytes meet antigen-presenting cells, activate, differentiate into effector cells and migrate to peripheral tissues causing the characteristic tissue damage of aGvHD. 8 Both CD62L and CCR7 are characteristically expressed by T-cells able to migrate through SLO including naïve and central memory T-cells. 12 The role of CD62L and CCR7 in the development of aGvHD has been demonstrated in animal models in which mice with T-cells lacking CD62L or CCR7 were unable to develop aGvHD or developed attenuated aGvHD. 13, 14 Unlike aGvHD, the pathogenesis of cGvHD is poorly understood and seems to involve thymic dysfunction, autorreactive lymphocytes, regulatory T-cells and Th1/Th2/Th17 responses. 7, 15, 16 Motivated by the probable role of the homing potential of the donor T-cells in the development of GvHD, and the lack of reliable laboratory diagnostic, prognostic or follow-up biomarkers of this complication, we aimed in this single center study, to determine whether the migratory capacity of the donor lymphocytes could be used to predict and/or treat GvHD.
METHODS

Donors and patients
This study enrolled 85 donor-recipient pairs who underwent allo-HSCT at the La Princesa University Hospital between 2011 and 2014. The study was approved by the local Ethics Committee and performed in accordance to the Declaration of Helsinki. Detailed clinical features of the patients are presented in Table 1 . aGvHD was classified on degrees I, II, III and IV and cGvHD as mild, moderate or severe according to the criteria of the Glucksberg score 2 and to the last consensus of the National Institutes of Health (NIH).
Chemotaxis assays
Peripheral blood mononuclear cells (PBMCs) from the apheresis were starved for 1 h in incomplete Roswell Park Memorial Institute medium. Chemotaxis was performed in Transwell chambers (6.5-mm diameter, 10-mm thickness, 5-micrometer diameter pore size; Costar, Cambridge, MA, USA) and included a basal migration control and chemokine stimulation using CCL19 and CCL21. In all cases, an upper chamber contained 5 × 10 5 cells. Incomplete Roswell Park Memorial Institute medium or 1 µg/ml CCL19 or CCL21 (PeproTech, Rocky Hills, NJ, USA) were added to the lower chambers. After 3 h at 37°C 5% CO 2 , cells in the lower chamber were collected and stained with anti-CD62L (FITC), anti-CCR7 (PE), anti-CD45 (PerCP), anti-CD3 (APC), anti-CD8 (APC-H7) and anti-CD4 (PB). The migrated cells were counted for 250 s in a FACSCANTO II flow cytometer from Becton Dickinson (BD) Biosciences (San José, CA, USA). The migratory index was defined as the cells migrated in response to CCL19 or CCL21, divided by the cells migrated in the basal well.
Phenotyping
A sample was collected from the apheresis product and stained with a seven-color panel of monoclonal antibodies: anti-CD8 (FITC), anti-CD4 (PB), anti-CD62L (PE), anti-CD3 (PerCP), anti-CD19 (PE-Cy7), anti-CD45 (PO) and anti-CCR7 (APC; R&D Systems, Minneapolis, MN, USA). All antibodies were purchased from BD unless stated otherwise. Fifty microlitres of whole-apheresis product was incubated in a Trucount tube (BD, Biosciences) with the antibodies for 10 min at room temperature. Then, RBCs were lysed for 10 min with Pharm lyse (BD Biosciences). Ten thousand CD45+CD3+ T-cells were acquired using a FACSCANTO II flow cytometer (BD) and analyzed with Infinicyt software (Cytognos, Salamanca, Spain). Relative proportions and absolute numbers of the different T-cell subsets according to the coexpression of CCR7 and CD62L were expressed as a percentage of the total WBCs (%WBC). Absolute numbers were calculated by multiplying that percentage by the total WBCs infused per kg.
Activation assay
PMBCs from healthy donors were placed in a 96-well plate at 10 5 cell/ml and stimulated overnight with pre-coated purified anti-CD3 (5 μg/ml, clone OKT 3, eBiosciences, San Diego, CA, USA) and anti-CD28 (5 μg/ml, clone CD28.2 eBiosciences), in the presence of anti-human CD40L (PE, BD) to detect CD4+ T-cell activation. Next day, the samples were stained with anti-CD4 (FITC), CD3 (PerCP) and CCR7 (BV) and acquired in a FACS Canto II flow cytometer. To detect CD8+ T-cell activation, PBMCs were stained 16 h after the stimulus with CD8 (FITC), CD69 (PE), CD3 (PerCP) and CCR7 (BV). Binary or Ordered logistic regression analysis, as appropriate, was performed to identify predictors of GvHD adjusted by confounding variables which included age (of the donor and recipient), HLA status, CMV status, sex (donor, recipient, and the relationship between them), conditioning regimen, thymoglobulin, number of CD3+ and CD34+ infused, allosensibilization, relapse post HSCT, base disease, source of graft and prophylaxis.
Statistical analysis
First, an exploratory univariate analysis was carried out to search for variables associated with the dependent variables (aGvHD and cGvHD; P ⩽ 0.05). Confounding variables reaching a probability threshold on univariate analysis (P ⩽ 0.10) were included in a multivariate logistic regression model. Survival immediately after the transplantation was analysed by groups (median percentage of CCR7 expression in the CD4+ and CD8+ cells), estimating and comparing survival curves by Kaplan-Meier method and log-rank test, respectively. Cox model regression was carried out to quantify risk factors for time (hazard ratio (HR)). Significance was set at a value of P ⩽ 0.05. Statistical analysis was performed using Stata version 13.0 (College Station, TX, USA).
RESULTS
T-cells infused into patients who develop GvHD migrate more towards CCR7 ligands than T-cells infused into patients who will not develop GvHD
To address whether GvHD correlated with a more efficient CCR7-dependent T-cell migration, we assessed the ex vivo migration of PBMCs from apheresis of 39 donors in response to Abbreviations: Csp = cyclosporine; F = female; HLA = human leukocyte antigen; M = male; MMF = mycophenolate mofetil; Mtx = methotrexate; PBSC = peripheral blood stem cell. 
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I Portero-Sainz et al either CCL19 or CCL21, the ligands of CCR7. The results were correlated post hoc with the development or not of GvHD at day 100 and 360 days post transplantation. Interestingly, the migratory index of the CD4+ and CD8+ T-cells toward CCL21, and mainly toward CCL19, from patients who develop GvHD within 100 days after HSCT was significantly higher than those from patients who would not develop GvHD (Figure 1 ). Similar results were obtained at day 360 post transplant (data not shown). These data indicated that the migratory capacity of the lymphocytes of the donor is clearly related to the development of GvHD and prompted us to study the relationship between GvHD and the expression of two of the most relevant molecules in the trafficking of lymphocytes towards SLO, CD62L and CCR7.
CD62L expression is lost in the apheresis and is therefore not a reliable biomarker for GvHD The initial transversal analysis of our data revealed that the percentage of CD62L+ lymphocytes in the apheresis product was very low compared with healthy lymphocytes and confirmed that CD62L undergoes plasma membrane shedding after G-CSF mobilization. [17] [18] [19] Once in the recipient, CD62L is reexpressed to high levels at the lymphocyte surface (Supplementary Figure 1) . Accordingly, no differences were seen in the expression of CD62L or the coexpression of CD62L and CCR7 between patients who develop GvHD and those who do not (data not shown). In conclusion, shedding of CD62L in response to G-CSF precludes this molecule as a biomarker for the development and severity of GvHD.
The proportion of CCR7+ T-cells is increased in the apheresis transplanted into patients who later develop GvHD and correlates with its degrees of severity We therefore focused on the role of CCR7 as biomarker of GvHD. To this end, we compared the absolute and relative numbers of CD4+ and CD8+ T-cells expressing CCR7 in the apheresis product that were transplanted into patients who would later develop GvHD and those who displayed no GvHD. Of note, both aGvHD and cGvHD groups were transplanted with the same relative and absolute numbers of whole CD3+, CD4+ and CD8+ T-cells (Supplementary Figure 2) . When CCR7 expression was included in the analysis to define subsets based on the migratory ability, a higher percentage of CD4+CCR7+ (9.4 vs 6.7%, P = 0.0426) and CD8+CCR7+ T-cells (5.1 vs 3.6%, P = 0.0257) were transplanted into patients who later developed cGvHD (Figures 2a and c) . No significant differences were observed when absolute numbers of the respective subsets were analyzed (Figures 2b and d) .
We next studied whether the severity of cGvHD (mild n = 12, moderate n = 11 and severe n = 12) correlated with the number of CCR7+ T-cells. We observed that the higher proportion of the CCR7+ T-cells in the graft the more severe the manifestations of the disease were. This was true for both the relative proportion and absolute numbers of CD8+ T-cells (no cGvHD 3.6% and 28.3 × 10 6 /kg; mild 3.7% and 22.7 × 10 6 /kg; moderate 5.9% and 43.7 × 10 6 /kg; severe 6% and 41.1 × 10 6 /kg, P = 0.024 and P = 0.047; Figures 2g and h) .
Conversely, aGvHD patients were transplanted with higher percentages and absolute numbers of CD4+CCR7+ T-cells (7.2 vs 10.35%, P = 0.0141 and 59.7 × 10 6 /kg vs 80.9 × 10 6 /kg, P = 0.0431) (Figures 3a and b) . When the aGvHD patients were subdivided based on the severity degree (grade I n = 5, grade II n = 11, grade III n = 2 and grade IV n = 7), significant differences were observed in the percentage of CD4+CCR7+ T-cells transplanted in those patients who developed any degree of aGvHD (no aGvHD 7.2% vs grade I 7.4% vs grade II 11.2% vs grade III 16.4% and vs grade IV 9.5%, P = 0.023; Figure 3e ). CCR7 can be used as biomarker for both aGvHD and cGvHD We next investigated the value of CCR7 to predict the development and severity of aGvHD and cGvHD. To this end, a multivariate analysis was performed which included confounding variables reaching a probability threshold Po0.1 on univariate analysis (sex, HLA, CMV status, thymoglobulin and relapse) and the independent variables (percentages of the different T-cell subsets) associated (P-value o0.05) with the dependent variables (aGvHD, cGvHD and severity degrees). Multivariate analysis in Table 2 confirmed that CCR7 expression is a risk factor for the development of GvHD. Of note, the percentage of CCR7+CD4+ T-cells increases the probability of developing aGvHD (odds ratio (OR) = 1.08, confidence interval (CI) (95%) = 1.01-1.16, P = 0.019) and suffering a higher degree (OR = 1.08, CI (95%) = 1.01-1.15, P = 0.014). Similarly, the OR of the percentage of CCR7+CD8+ T-cells was 1.17 (CI (95%) = 1.01-1.36, P = 0.0031) and 1.21 (CI (95%) = 1.05-1.39, P = 0.006) for the development of cGvHD and its degrees, respectively. Proportion of infused T-cells subpopulations in the apheresis comparing No GvHD vs cGvHD or its severity. Apheresis samples were analysed by flow cytometry and were divided between those infused into patients who will develop cGvHD (n = 35) and the ones who will not (n = 30). Percentage and absolute numbers of CD4+ (a and b) and CD8+ (c and d) subpopulations infused into patients with or without cGvHD. Percentage and absolute numbers of CD4+ (e and f) and CD8+ (g and h) subpopulations infused into patients divided in severity degrees of the cGvHD. No cGvHD (n = 30), mild (n = 12), moderate (n = 11), severe 3 (n = 12). Associations were studied by analysis of variance or Kruskal-Wallis test.
CCR7 expression correlates with survival
To study whether the percentage of CCR7+ T-cells in the apheresis correlates with short-term survival after the transplantation, the patients were divided by setting a cut-off equal to the median percentage of CCR7 expression in the CD4+ (5.9%) and CD8+ (3.6%) T-cells. Patient survival was followed for 100 days. The median survival period was higher in those patients transplanted with less than 5.96% CD4+CCR7+ (82 vs 57 days; log rank P = 0.06; Figure 4a ) or 3.6% CD8+CCR7+ T-cells (82 vs 52 days; log rank P = 0.02; Figure 4b ). Proportion of infused T-cells subpopulations in the apheresis comparing No GvHD vs aGvHD or its severity. Apheresis samples were analysed by flow cytometry and were divided between those infused into patients patients who will develop aGvHD (n = 25) and the ones who will not (n = 38). Percentage and absolute numbers of CD4+ (a and b) and CD8+ (c and d) subpopulations infused into patients with or without aGvHD. Percentage and absolute numbers of CD4+ (e and f) and CD8+ (g and h) subpopulations infused into patients divided in severity degrees of the aGHVD. No aGvHD (n = 38), grade 1 (n = 5), grade 2 (n = 11), grade 3 (n = 2) and grade 4 (n = 7). Associations were studied by analysis of variance or Kruskal-Wallis test.
The Cox regression model confirmed that the patients receiving percentages over the median of CD8+CCR7+ T-cells (HR = 3.79; CI (95%) = 1.09-13.21, P = 0.036) showed a higher probability of death. A second Cox regression was performed to quantify the risk of dying while the percentage of CD4+CCR7+ or CD8+CCR7+ expression is increased in the patients. The HR of the percentage of CD4+CCR7+ T-cells was 1.065 (CI (95%) = 1.01-1.13, P = 0.055) and the HR of the percentage of CD8+CCR7+ T-cells was 1.14 (CI (95%) = 1.01-1.31, P = 0.05). Therefore, receiving a high proportion of CCR7+ T-cells may have a negative impact in the survival, at least during the first months after the transplant.
CCR7+ T-cells undergo more efficient activation than CCR7 negative T-cells after in vitro stimulation To study the potential for activation of CCR7+ T-cells, we carried out ex vivo activation assays with PBMCs from healthy donors using anti-CD3 and anti-CD28 mAbs. Expression of CD40L on CD4+ T-cells and of CD69 on CD8+ T-cells were used as markers of activation. Interestingly, we found higher expression of CD40L in the CD4+ T-cells expressing CCR7 (P = 0.004; Figure 5a ) as well as higher expression of CD69 in the CD8+CCR7+ T-cells (P = 0.008; Figure 5b ) compared with the CCR7-negative subsets. In particular, when T-cells subsets were analysed according to CD45RA and CCR7 expression, naïve T-cells, both CD4+ T-cells and CD8+ T-cells, are more activated than central memory or effector T-cells (P = 0.04 and P = 0.0035; Figures 5c and d) .
DISCUSSION
In this study, we aimed to demonstrate whether the potential of homing into SLO is relevant to causing GvHD. To our knowledge this is the first analysis of the influence of the migratory capacity of the donor T-cells on clinical outcome following allogeneic HSCT. Our data indicate that the cells with the highest homing potential towards chemokines produced in the SLO are responsible for the development of GvHD. Consequently, the migratory index measurement would help to predict which patients are more susceptible to develop GvHD. As a surrogate index of the migratory potential of T-cells, we quantified CCR7+ T-cells in the apheresis. Multivariate analysis demonstrated that the percentage of CCR7+ T-cells is an independent predictive factor for the development and severity of GvHD, both acute and chronic. Therefore, CCR7 could be considered as a biomarker for predicting the risk of suffering GvHD.
CCR7+ T-cells include naïve, central memory and the recently defined stem cell memory T-cells. 12, 20 Different experimental models demonstrated that alloreactive T-cells are mostly derived from naïve T-cells. 21 However, only two studies 22, 23 have analyzed the influence of different T-cell subsets in the apheresis on clinical outcome after an allogeneic T-replete HSCT. First, Yakoub-Agha et al. 22 demonstrated that the proportion of the whole CD4+CCR7+ T-cells (but not the proportion of naïve CD45RA+ CCR7+ T-cells) in the graft influences the development and severity of aGvHD. Their findings support our functional data which demonstrate that the comprehensive homing potential of the donor T-cells in response to CCR7 ligands is crucial to the clinical outcome. More recently, Waller et al. could not find any association between naïve T-cells in the peripheral blood stem cell grafts and GvHD. Compared with our study and that from Yakoub-Agha et al., 22 Waller et al. 23 did not study the numbers of CCR7-expressing T-cells but quantified the absolute numbers of naïve T-cells defined as CD45RA+ CD62L+ T-cells or triple-positive CD45RA+ CD62L+ CCR7+ T-cells. With this strategy they are not evaluating the influence of the total CCR7+ T-cells in the clinical outcome. Moreover, in the case of peripheral blood grafts, CD62L is lost as a consequence of the apheresis procedure [17] [18] [19] (Supplementary Figure 1 ) and therefore they are probably underestimating the numbers of naïve T-cells.
A possible criticism to our study is that both aGvHD and cGvHD were correlated to the percentage, but not to the cell dose of CD4+CCR7+ and CD8+CCR7+ T-cells, respectively. It is possible that once a 'security threshold' is exceed, the absolute numbers of the different subsets of the transplanted T-cells are not directly proportional to GvHD. In this scenario, the homing function of CCR7 and the extensive replicative capacity of CCR7+ T-cells that reach the SLO 12, 24 could explain the fact that it is the migratory index of T-cells and to a lesser extent the percentage of CCR7+ T-cells, the parameters that better correlate with the development and severity of GvHD. Based on the experimental models which proposed naïve T-cells as the main source of alloreactivity, several groups have recently depleted CD45RA+ T-cells from the graft to reduce GvHD since CD45RA+ is considered a bona fide marker of naïve T-cells. Differences in the patient populations, donor sources and conditioning regimens preclude clear conclusions from those studies. [25] [26] [27] [28] In one of them Bleakley et al. 25 demonstrate that depleting CD45RA+ T-cells reduced the incidence of cGvHD but not that of aGvHD. They discuss that alloreactive T-cells are possibly also included among central memory CD45RA-CD45RO+CCR7+ T-cells which conserve the homing potential to the SLO. Accordingly, we here propose that the alloreactivity of the T-cells is related to the comprehensive capability of the donor CCR7+ T-cells to reach the replicative niches in the SLO. Accordingly, the depletion of CCR7+ T-cells may be a promising alternative for the prevention or reduction of GvHD, both acute and chronic. To provide further insight in this field, we ideally would like to compare T-cell replete, CD45RA+CCR7+ naïve T cell-depleted and CCR7+ T cell-depleted allogeneic HSCT in a prospective randomized controlled clinical trial, the outcome being GvHD development, immune reconstitution and relapse.
As a conclusion, CCR7 is a promising GvHD biomarker identified on a hypothesis-driven approach and supported with numbers and functional data. The quantification of CCR7+ T-cells and their migratory index by flow cytometry is easy, rapid, susceptible of standardization and does not need extra samples from the donor or the recipient. Therefore, we are proposing its validation in a prospective and multicenter clinical trial, large enough to allow clinical application.
Last but not least CCR7 might be a novel therapeutic target for specific patients to avoid or ameliorate the incidence and severity of GvHD, the ultimate goal being personalized allogeneic HSCT.
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